arailkar
☆    

2020-05-29 17:21
(808 d 21:35 ago)

Posting: # 21491
Views: 1,246
 

 Bioequivalence for Parenteral Products [Regulatives / Guidelines]

Dear Helmut,

I am interested in finding out if bioequivalence study is needed in the US when an IV formulation is changed to a subcutaneous formulation. I would also appreciate if you can please give me references to US FDA Guidance document that addresses this topic. Thank you very much.

Regards,
Ani
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2020-05-29 17:51
(808 d 21:05 ago)

@ arailkar
Posting: # 21492
Views: 817
 

 T = EV ∧ R = IV ¬ BE (→ absolute BA)

Hi Ani,

» Dear Helmut,

     ▲▲▲▲▲▲ Not interested in opinions of others?


» I am interested in finding out if bioequivalence study is needed in the US when an IV formulation is changed to a subcutaneous formulation.

That’s not BE but absolute bioavailability.

» I would also appreciate if you can please give me references to US FDA Guidance document that addresses this topic.

Contrary to IV, in SC you have an absorption site. Hence, calling that a “formulation change” is an euphemism. The NDA/IND guidance is a starter.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
22,302 posts in 4,667 threads, 1,585 registered users;
online 11 (0 registered, 11 guests [including 5 identified bots]).
Forum time: Tuesday 14:56 CEST (Europe/Vienna)

In matters of style, swim with the current;
in matters of principle, stand like a rock.    Thomas Jefferson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5